Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spravato (esketamine)
Pharma
FDA signs off on Johnson & Johnson's Spravato as a monotherapy
Johnson & Johnson’s depression nasal spray Spravato has received another potential boost as the FDA will allow it to be used as a monotherapy.
Kevin Dunleavy
Jan 21, 2025 3:23pm
J&J expects 25 blockbuster drugs to drive future sales growth
Dec 5, 2023 4:42pm
J&J takes major hit from litigation cost in 2023's first quarter
Apr 18, 2023 11:15am
J&J builds case for Spravato in tough-to-treat depression
Nov 23, 2022 10:05am
NICE's rebuff of J&J depression nasal spray under scrutiny
Sep 8, 2022 10:15am
Axsome gets depression drug Auvelity over the FDA finish line
Aug 19, 2022 10:55am
